kaonavi
4435
D. Western Therapeutics Institute
4576
Itamiarts
168A
Nakayo
6715
Allied Telesis Holdings KK
6835
(Q3)Dec 31, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 2.07%131.91B | 8.70%121.44B | 7.47%472.4B | 1.19%117B | 17.50%129.24B | -5.02%114.44B | 19.53%111.73B | 14.90%439.57B | 12.59%115.62B | 9.17%109.99B |
Cost of revenue | -1.32%102.11B | 1.51%97.95B | 9.25%389.51B | 7.99%97.57B | 14.15%103.48B | -4.67%91.97B | 22.07%96.49B | 14.38%356.52B | 6.34%90.36B | 11.22%90.65B |
Gross profit | 15.71%29.8B | 54.18%23.49B | -0.20%82.89B | -23.11%19.43B | 33.16%25.75B | -6.45%22.47B | 5.63%15.24B | 17.18%83.05B | 42.51%25.27B | 0.49%19.34B |
Operating expense | 29.22%16.05B | 20.61%13.95B | 1.53%47.06B | -0.14%11.01B | 0.44%12.42B | 2.35%12.06B | 3.53%11.57B | 7.44%46.34B | -3.25%11.02B | 14.27%12.36B |
Operating profit | 3.13%13.75B | 160.16%9.54B | -2.38%35.84B | -40.89%8.42B | 91.17%13.34B | -14.93%10.41B | 12.84%3.67B | 32.32%36.71B | 124.74%14.25B | -17.21%6.98B |
Net non-operating interest income (expenses) | 11.27%1.17B | 4.65%1.13B | 74.77%4.26B | 42.32%1.13B | 63.08%1.05B | 77.15%1.01B | 148.50%1.08B | 51.15%2.44B | 83.37%794M | 32.10%642M |
Non-operating interest income | 16.62%1.3B | 18.68%1.31B | 69.42%4.44B | 41.73%1.17B | 54.58%1.11B | 75.12%1.06B | 132.70%1.1B | 53.79%2.62B | 82.26%822M | 40.90%720M |
Non-operating interest expense | 101.52%133M | 225.93%88M | -2.76%176M | 25.00%35M | -15.38%66M | 41.18%48M | -34.15%27M | 101.11%181M | 55.56%28M | 212.00%78M |
Total other finance cost | ---- | --95M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Net investment income | 69.92%-160M | -40.39%893M | 76.80%4.01B | 21.12%1.88B | 55.37%-532M | -0.34%1.16B | 102.16%1.5B | -24.58%2.27B | -29.60%1.55B | -993.58%-1.19B |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | 188.95%6.22B | 97.78%3.75B | 965.95%2.47B | 301.68%2.15B | 824.39%1.9B | 14.85%232M | |||
Income from associates and other participating interests | -82.30%148M | -78.30%107M | 11.30%3.48B | 35.25%1.41B | 15.47%836M | -6.46%739M | -13.20%493M | 49.50%3.12B | 48.93%1.04B | 25.69%724M |
Special income (charges) | 54.73%-3.02B | 111.13%116M | -370.87%-11.27B | 54.45%-538M | -1,170.67%-6.67B | -356.43%-3.02B | -3,907.69%-1.04B | -61.91%-2.39B | -1,394.94%-1.18B | -34.96%-525M |
Less:Restructuring and mergern&acquisition | --0 | ---2.37B | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Less:Other special charges | -71.95%1.25B | 116.40%2.03B | 548.41%6.74B | -59.54%157M | 1,563.06%4.46B | 231.65%1.18B | 3,511.54%939M | -29.70%1.04B | 391.14%388M | -31.11%268M |
Less:Write off | -20.05%1.77B | 117.48%224M | 234.64%4.53B | -51.95%381M | 761.48%2.21B | 502.96%1.83B | --103M | --1.35B | --793M | --257M |
Other non-operating income (expenses) | -371.88%-87M | -74.11%51M | -18.07%485M | 68.06%321M | -69.23%32M | -129.41%-65M | 159.21%197M | -73.84%592M | -67.52%191M | -88.05%104M |
Income before tax | 12.15%11.8B | 100.99%11.83B | -4.17%43.02B | -11.68%16.37B | 51.13%10.52B | -28.63%10.24B | 16.74%5.89B | 25.48%44.89B | 78.39%18.54B | -30.83%6.96B |
Income tax | -14.23%2.39B | 64.71%3.68B | -7.98%9.76B | -57.17%1.78B | 89.54%2.79B | -23.29%2.97B | 98.14%2.23B | 20.66%10.61B | 100.43%4.15B | -52.07%1.47B |
Net income | 21.68%9.41B | 123.17%8.15B | -2.99%33.25B | 1.44%14.6B | 40.83%7.73B | -30.62%7.28B | -6.69%3.65B | 27.05%34.28B | 72.92%14.39B | -21.51%5.49B |
Net income continuous operations | 21.67%9.41B | 123.17%8.15B | -2.99%33.25B | 1.43%14.6B | 40.83%7.73B | -30.61%7.28B | -6.69%3.65B | 27.05%34.28B | 72.92%14.39B | -21.50%5.49B |
Noncontrolling interests | -5.61%1.82B | 78.24%2.33B | -13.16%6.76B | -1.59%1.92B | 11.02%1.92B | -41.69%1.61B | -2.61%1.31B | 40.61%7.78B | 15.24%1.95B | 14.84%1.73B |
Net income attributable to the company | 30.71%7.59B | 148.15%5.82B | 0.00%26.5B | 1.92%12.68B | 54.54%5.81B | -26.67%5.67B | -8.78%2.35B | 23.55%26.5B | 87.67%12.44B | -31.49%3.76B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 30.71%7.59B | 148.15%5.82B | 0.00%26.5B | 1.92%12.68B | 54.54%5.81B | -26.67%5.67B | -8.78%2.35B | 23.55%26.5B | 87.67%12.44B | -31.49%3.76B |
Gross dividend payment | ||||||||||
Basic earnings per share | 37.87%48.97 | 154.45%36.31 | 0.06%162.41 | 3.24%78.11 | 59.57%35.52 | -28.57%34.51 | -11.31%14.27 | 21.36%162.32 | 82.75%75.66 | -34.95%22.26 |
Diluted earnings per share | 37.90%48.97 | 154.45%36.31 | 0.06%162.41 | 4.02%78.11 | 59.52%35.51 | -28.57%34.51 | -11.31%14.27 | 21.38%162.32 | 81.42%75.0881 | -34.95%22.26 |
Dividend per share | 0 | 0 | 10.00%55 | 12.00%28 | 0 | 8.00%27 | 0 | 0.00%50 | 0.00%25 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |